AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now, European Medical Agency (EMA) is investigating potential clotting risks from Johnson & Johnson’s (NYSE: JNJ) one-shot COVID-19 vaccine, reports Yahoo Finance.
What Happened?
While AstraZeneca has been caught in a frenzy over possible links to rare blood clots and subsequent restriction on the usage of its vaccine, this is a formal disclosure...
https://mfame.guru/alternative-to-oxford-astrazeneca-vaccine/